This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Quotient 미래 성장

Future 기준 확인 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Quotient.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Medical Equipment 수익 성장	15.8%
매출 성장률	n/a
향후 자기자본 수익률	n/a
애널리스트 커버리지	None
마지막 업데이트	n/a

최근 미래 성장 업데이트

Recent updates

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Quotient 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

DB:U4W0 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2022	37	-124	-114	-112	N/A
9/30/2022	38	-156	-127	-125	N/A
6/30/2022	38	-137	-125	-123	N/A
3/31/2022	39	-125	-122	-119	N/A
12/31/2021	38	-139	-120	-117	N/A
9/30/2021	37	-125	-110	-106	N/A
6/30/2021	44	-113	-90	-85	N/A
3/31/2021	43	-111	-82	-78	N/A
12/31/2020	42	-96	-77	-73	N/A
9/30/2020	42	-92	-73	-69	N/A
6/30/2020	33	-105	-85	-80	N/A
3/31/2020	33	-103	-85	-81	N/A
12/31/2019	32	-105	-85	-79	N/A
9/30/2019	31	-103	-83	-77	N/A
6/30/2019	29	-104	-84	-80	N/A
3/31/2019	29	-105	-80	-76	N/A
12/31/2018	27	-99	-84	-77	N/A
9/30/2018	26	-93	-88	-77	N/A
6/30/2018	26	-87	-88	-70	N/A
3/31/2018	25	-82	-90	-68	N/A
12/31/2017	24	-83	-89	-66	N/A
9/30/2017	23	-93	-83	-60	N/A
6/30/2017	23	-89	-81	-62	N/A
3/31/2017	22	-85	-76	-56	N/A
12/31/2016	22	-74	-71	-47	N/A
9/30/2016	21	-53	N/A	-49	N/A
6/30/2016	19	-40	N/A	-49	N/A
3/31/2016	19	-34	N/A	-47	N/A
12/31/2015	17	-27	N/A	-51	N/A
9/30/2015	17	-59	N/A	-40	N/A
6/30/2015	17	-67	N/A	-33	N/A
3/31/2015	18	-59	N/A	-27	N/A
12/31/2014	19	-62	N/A	-18	N/A
9/30/2014	19	-23	N/A	-15	N/A
6/30/2014	19	-13	N/A	-7	N/A
3/31/2014	20	-10	N/A	-4	N/A
12/31/2013	19	-7	N/A	-6	N/A
9/30/2013	18	-5	N/A	-5	N/A
6/30/2013	17	-3	N/A	-6	N/A
3/31/2013	14	-5	N/A	-4	N/A

애널리스트 미래 성장 예측

수입 대 저축률: Insufficient data to determine if U4W0's forecast earnings growth is above the savings rate (0.2%).

수익 vs 시장: Insufficient data to determine if U4W0's earnings are forecast to grow faster than the German market

고성장 수익: Insufficient data to determine if U4W0's earnings are expected to grow significantly over the next 3 years.

수익 대 시장: Insufficient data to determine if U4W0's revenue is forecast to grow faster than the German market.

고성장 수익: Insufficient data to determine if U4W0's revenue is forecast to grow faster than 20% per year.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: Insufficient data to determine if U4W0's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Quotient 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Quotient Limited Provides Earnings Guidance for the Fiscal Year Ending March 31, 2023

Quotient Limited Provides Earnings Guidance for the Fiscal Year 2023

Quotient Limited Provides Revenue Guidance for the First Quarter and Full Year Ending March 31, 2022

Recent updates

Quotient Limited Appoints James Harman Gaudin to its Board of Directors

Quotient Limited Filed for Bankruptcy

Quotient Limited(OTCPK:QTNT.F) dropped from NASDAQ Composite Index

Quotient Limited Announces Resignation of Franz Walt as Director

Quotient Announces Intent to Voluntary Delist from the Nasdaq Global Market

High number of new directors

Quotient Limited Announces the Retirement of Brian McDonough as Member of the Board of Directors

High number of new directors

High number of new directors

Independent Chairman of the Board recently bought €140k worth of stock

Quotient Limited Appoints Sophie Bechu as A Director

Quotient Receives Non-Compliance Letter from Nasdaq

First quarter 2023 earnings released: US$0.37 loss per share (vs US$0.27 loss in 1Q 2022)

Quotient Limited Provides Earnings Guidance for the Fiscal Year Ending March 31, 2023

Quotient Limited to Report Q1, 2023 Results on Aug 09, 2022

Quotient Limited, Annual General Meeting, Oct 31, 2022

Quotient Limited Announces Executive Changes

Quotient Limited Provides Earnings Guidance for the Fiscal Year 2023

Full year 2022 earnings released: US$1.23 loss per share (vs US$1.18 loss in FY 2021)

Quotient Limited to Report Q4, 2022 Results on Jun 22, 2022

Quotient Limited and Theradiag Announce Partnership to Advance Autoimmune Disease Diagnostics

Quotient Receives Non-Compliance Letter from Nasdaq

Quotient Receives Non-Compliance Letter from Nasdaq

Quotient Limited Appoints Thomas Aebischer to Quotient Board of Directors, Effective as of May 1, 2022

Quotient Limited Appoints Manuel O. Méndez as Director

Quotient Limited Appoints Thomas Aebischer to Board of Directors, Effective as of May 1, 2022

Independent Chairman of the Board recently bought €70k worth of stock

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Quotient Limited to Report Q3, 2022 Results on Feb 08, 2022

Chief Commercial Officer recently bought €91k worth of stock

Second quarter 2022 earnings released: US$0.27 loss per share (vs US$0.16 loss in 2Q 2021)

Chief Commercial Officer Jeremy Stackawitz has left the company

First quarter 2022 earnings released: US$0.24 loss per share (vs US$0.32 loss in 1Q 2021)

Full year 2021 earnings released: US$1.18 loss per share (vs US$1.44 loss in FY 2020)

Quotient Limited Provides Revenue Guidance for the First Quarter and Full Year Ending March 31, 2022

Quotient Limited announced that it has received $95 million in funding from Highbridge Capital Management, LLC, CI Global Asset Management, Russell Investments Canada Ltd., Whitebox Advisors, LLC

Quotient Limited announced that it expects to receive $95 million in funding from Highbridge Capital Management, LLC and other investors

New 90-day low: €3.90

Quotient Limited Announces Manuel Mendez as Chief Executive Officer, Effective April 1, 2021

Chief Commercial Officer recently sold €129k worth of stock

New 90-day low: €4.06

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.37 loss in 3Q 2020)

Revenue beats expectations

Quotient Limited to Report Q3, 2021 Results on Feb 01, 2021

Quotient Limited Announces Resignation of Ed Farrell from His Position as Chief Operating Officer

Quotient Limited Provides Status Update on the Initial SDS Microarray and MosaiQ Instrument for the US Market

New 90-day high: €5.30

Second quarter 2021 earnings released: US$0.18 loss per share

Revenue beats expectations

Quotient Limited to Report Q2, 2021 Results on Nov 02, 2020

Quotient Limited Receives Receipt of U.S. FDA Emergency Use Authorization or Mosaiq COVID19 Antibody Test

Quotient Limited has completed a Follow-on Equity Offering in the amount of $75.000001 million.

New 90-day low - €4.54

New 90-day low - €5.60

Earnings released

Quotient Limited to Report Q1, 2021 Results on Aug 03, 2020

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견